Collegium Pharmaceutical (COLL) EBT Margin (2016 - 2026)

Collegium Pharmaceutical has reported EBT Margin for 11 years, with the latest figure at 6.77% in Q2 2026.

• On a quarterly basis, EBT Margin fell 1583.0% year-over-year to 6.77% in Q2 2026; TTM through Jun 2026 was 9.61%, a 212.0% increase from a year earlier, with the FY2025 full-year figure at 11.87%, down 374.0% from the prior year.
• EBT Margin was 6.77% for Q2 2026 at Collegium Pharmaceutical, down from 9.68% in the prior quarter.
• The five-year high for EBT Margin was 31.19% in Q4 2023, with the low at 18.92% in Q1 2022.
• Average EBT Margin over 5 years is 7.65%, with a median of 9.59% recorded in 2024.
• The largest YoY upside for EBT Margin was 13654 bps in 2022 against a maximum downside of 3656 bps in 2022.
• Over 5 years, EBT Margin stood at 5.54% in 2022, then jumped by 663 bps to 31.19% in 2023, then slumped by 70 bps to 9.49% in 2024, then surged by 49 bps to 14.13% in 2025, then plunged by 148 bps to 6.77% in 2026.
• The last three EBT Margin figures came in at 6.77% (Q2 2026), 9.68% (Q1 2026), and 14.13% (Q4 2025), per Business Quant data.